glp 1 cgm GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP‑1 weight loss you can
Description
Please click the button below to indicate that you are
Sympathetic nervous system effects may contribute to heart rate changes
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
For women using GLP-1 medications, these lifestyle factors can pose additional challenges
Intestinal hormones
Symptoms that persist beyond the initial 812 weeks of therapy, worsen over time, or significantly impair nutritional intake warrant further evaluation
